VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CDTXCidara Therapeutics, Inc.
$221.38$7.0B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksCDTXQuarterly Cash Flow

Cidara Therapeutics, Inc. (CDTX) Quarterly Cash Flow Statement

120+ quarters historyFree accessUpdated daily

Cidara Therapeutics, Inc. (CDTX) quarterly cash flow statement — complete operating, investing & financing history

CDTX Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricQ3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23Q3'23Q2'23Q1'23Q4'22
Cash from Operations-40.62M-40.96M-21.95M-29.41M-36.7M-103.78M-6.64M-12.72M-1.63M2.82M-10.9M-21M
Operating CF Margin %------34364.24%-682.84%-72.35%-17.73%55.44%-41.74%-205.52%
Operating CF Growth %-10.68%60.53%-230.37%-131.21%-2145.72%-3777.53%39.03%39.42%-105.84%123.84%53.84%-40.89%
Net Income-83.23M-25.72M-23.48M-52.31M-12.98M-89.41M-10.33M-5.61M-9.11M-12.36M3.01M-13.38M
Depreciation & Amortization28K27K49K59K61K57K56K39K22K-263K32K315K
Stock-Based Compensation3.17M2.96M1.74M1.66M751K703K795K830K796K795K640K673K
Deferred Taxes05.51M-5.51M000000000
Other Non-Cash Items160K-9.13M422K307K-2.7M460K220K2.69M269K229K737K-1.77M
Working Capital Changes39.26M-14.6M4.83M20.87M-21.82M-15.59M2.61M-10.67M6.39M14.42M-15.32M-6.84M
Change in Receivables-2K-165K05K650K4.66M8.96M-13.07M2.31M20.34M-20.29M-791K
Change in Inventory000007.27M-1.17M-3.2M-513K-1.95M00
Change in Payables63.56M-12.59M7.78M5.42M3.16M-4.73M-4.85M2.68M3.33M-246K3.19M-2.37M
Cash from Investing-176.47M0185K0-106K0-23K-178K-126K-107K-94K-9K
Capital Expenditures0000-106K0-23K-178K-126K-107K-94K-9K
CapEx % of Revenue------2.36%1.01%1.37%2.1%0.36%0.09%
Acquisitions00185K000000000
Investments------------
Other Investing-176.47M00000000000
Cash from Financing160K383.38M77K98.2M-182K239.13M-93K8K0-261K26.24M664K
Debt Issued (Net)00-50K-76K-75K-75K-50K00000
Equity Issued (Net)-1000K1000K127K1000K-107K1000K-4K1K0-261K1000K664K
Dividends Paid000000000000
Share Repurchases000000000000
Other Financing1.38M137K046K04K-39K7K0014K0
Net Change in Cash-216.93M342.42M-21.69M68.79M-36.98M135.35M-6.76M-12.89M-1.76M2.45M15.24M-20.35M
Free Cash Flow-40.62M-40.96M-21.95M-29.41M-36.8M-103.78M-6.67M-12.9M-1.76M2.71M-10.99M-21.01M
FCF Margin %------34364.24%-685.2%-73.37%-19.1%53.34%-42.1%-205.61%
FCF Growth %-10.36%60.53%-229.23%-128.02%-1990.97%-3922.47%39.35%38.6%-106.29%122.91%53.6%-40.95%
FCF per Share-2.61-2.63-1.55-3.02-5.64-22.74-1.47-2.85-0.390.60-2.17-5.84
FCF Conversion (FCF/Net Income)0.49x1.59x0.93x0.56x2.30x1.14x0.64x2.27x0.18x-0.21x-3.62x1.57x
Interest Paid000000000000
Taxes Paid0000000146K63K000